Part Used : ไม่ระบุ
Activity : DRUG INTERACTION
Solvent/Active Compound : myristicin
Type of experiment : in vivo
Type of animal : rat
N(Total) : -
N(Treatment) : -
Route : Intraperitoneal
Dose/Conc.(herb) : Myristicin 30 mg/kg (dissolved in corn oil)
Duration : 30 minutes
Type of interaction : Pharmacodynamics
Interaction with drug : Midazolam*/Versed/Dormicum
Dose/Conc.(drug) : 1.5 mg/kg
Remark : Results: a significant increase in fine motor movement of rats was found in the flumazenil plus myristicin group compared with the myristicin group (P = .039); flumazenil plus myristicin group versus the midazolam group (P < .001); and the flumazenil plus myristicin group compared with the midazolam plus myristicin group (P = .001). A decrease in fine motor movements was found in the midazolam group compared with the myristicin group (P = .046); and the midazolam plus myristicin group compared with the control group (P = .002).
Note : The data suggest, myristicin does not decrease anxiety by modulation of the GABAA receptor but may promote anxiogenesis. When myristicin was combined with midazolam, and antagonist-like effect similar to the flumazenil and myristicin combination was exhibited by a decrease in anxiolysis compared with the midazolam-only group. Myristicin may antagonize the anxiolytic effects of midazolam, increase anxiety, and affect motor movements.
